In 2026, most Americans pay $35 or less per month for insulin thanks to federal Medicare price caps and voluntary commercial insurance caps from the three major manufacturers. Biosimilar insulins, manufacturer savings cards, and patient assistance programs further reduce costs — sometimes to zero — for those who qualify.
Insulin Pricing in 2026
Insulin pricing in the US has shifted dramatically since 2022. The Inflation Reduction Act capped Medicare beneficiaries’ out-of-pocket cost at $35 per month per insulin product starting in 2023. In response, Eli Lilly, Novo Nordisk, and Sanofi voluntarily lowered list prices and expanded their commercial savings caps in 2024.
| Insulin product | Manufacturer | 2026 list price (vial) | Out-of-pocket with savings card |
|---|---|---|---|
| Humalog (insulin lispro) | Eli Lilly | ~$66 | $35 |
| Lyumjev | Eli Lilly | ~$66 | $35 |
| Insulin Lispro (Lilly authorized generic) | Eli Lilly | ~$25 | $25 or less |
| NovoLog (insulin aspart) | Novo Nordisk | ~$72 | $35 |
| Insulin Aspart (Novo authorized generic) | Novo Nordisk | ~$36 | $35 |
| Lantus (insulin glargine) | Sanofi | ~$64 | $35 |
| Semglee (interchangeable biosimilar) | Viatris/Biocon | ~$24 | $24 or less |
| Rezvoglar (interchangeable biosimilar) | Eli Lilly | ~$22 | $22 or less |
| Tresiba (insulin degludec) | Novo Nordisk | ~$110 | $35 |
| Levemir (insulin detemir) | Novo Nordisk | discontinued 2024 | — |
Pricing reflects publicly available 2025-2026 figures and may vary by pharmacy and pack size. Pen pricing is generally 30-50% higher than vials.
Brand vs Biosimilar Insulin
Insulin is a biologic medication, meaning it is grown in living cells rather than synthesized chemically. Biologics cannot have traditional “generics,” but they can have biosimilars — copies that are highly similar to the brand-name product with no clinically meaningful differences in safety or effectiveness.
Interchangeable Biosimilars
An “interchangeable” designation, granted by the FDA, means a pharmacist can substitute the biosimilar for the brand without a new prescription, just like a generic substitution. As of 2026:
- Semglee — interchangeable biosimilar to Lantus (insulin glargine)
- Rezvoglar — interchangeable biosimilar to Lantus
- Insulin Lispro Injection — Lilly’s authorized generic of Humalog
- Insulin Aspart Injection — Novo’s authorized generic of NovoLog
These products typically cost 65-85% less than the original branded insulin and are fully reimbursed by most insurers.
The $35 Monthly Cap Explained
Medicare Beneficiaries
If you have Medicare Part D, your out-of-pocket cost for any covered insulin is capped at $35 per month per prescription. There is no deductible to meet first. Medicare Part B-covered insulin (used in pumps) follows the same $35 cap. This applies to all 50 states and is permanent under federal law.
Commercial Insurance
The federal $35 cap does not legally apply to private insurance, but the three major insulin makers voluntarily extended the cap to commercially insured and uninsured patients through their savings programs:
- Eli Lilly Insulin Value Program — $35/month for all Lilly insulins
- Novo Nordisk MyInsulinRx — $35/month for NovoLog and Tresiba
- Sanofi Insulins Valyou Savings Program — $35/month for Lantus and other Sanofi insulins
Some states (Colorado, Illinois, Maine, New Mexico, Washington, and others) have passed laws capping commercial copays between $25-$100 per month.
Manufacturer Patient Assistance Programs
If you are uninsured or underinsured and earn up to 400% of the federal poverty level (about $60,240 for an individual in 2026), you may qualify for free insulin through:
- Lilly Cares Foundation — free Lilly insulins for qualifying patients
- Novo Nordisk Patient Assistance Program — free Novo insulins; up to 120-day supply
- Sanofi Patient Connection — free Sanofi insulins
Each program has its own application process and income verification requirements. Apply through the manufacturer’s website or with help from your prescriber’s office.
Other Cost-Saving Strategies
- GoodRx and Mark Cuban Cost Plus Drugs — Cost Plus offers some insulins at near-wholesale price plus a small markup.
- 340B clinics and FQHCs — Federally Qualified Health Centers can dispense insulin at deeply discounted rates.
- Walmart ReliOn — Walmart’s private label includes ReliOn NovoLog ($73/vial) and older NPH/Regular insulin (~$25/vial). Older insulins require careful timing but remain effective.
- Mail-order pharmacies — 90-day supplies can lower per-month cost by 10-30%.
- Pen vs vial — vials are usually cheaper per unit; pens are more convenient.
- Switch products — ask your provider whether a biosimilar or authorized generic could replace your current insulin.
What If You’re Uninsured
The cheapest legitimate path for an uninsured adult in 2026 is:
- Apply to a manufacturer Patient Assistance Program for free insulin.
- If denied, use the manufacturer’s $35 savings card.
- Compare prices at Mark Cuban Cost Plus Drugs, GoodRx, and Walmart ReliOn.
- Visit a 340B-eligible community health center for income-based pricing.
- Check if your state has a copay cap or an emergency insulin program.
Never ration insulin. Skipping doses to save money can cause diabetic ketoacidosis within hours and is life-threatening.
Insulin Cost vs Other Diabetes Care
For patients with type 2 diabetes, your provider may also discuss alternatives or add-ons such as metformin and GLP-1 receptor agonists. Compare options in our guides to diabetes medications, medicine for diabetes, and the broader treatment overview.
The Bottom Line
Insulin cost in 2026 is more manageable than at any point in the past decade. Medicare’s $35 cap is permanent, all three major manufacturers offer voluntary $35 commercial caps, biosimilars cut prices on long-acting analogs, and patient assistance programs can provide free insulin for qualifying patients. If you are paying more than $35 a month, you almost certainly have a lower-cost path — talk to your prescriber, pharmacist, or a manufacturer’s helpline today.
